| Literature DB >> 30386554 |
Fei Liu1,2, Zhifeng Wang2,3, Fangfang Liu4, Jinzhao Xu2,3, Qibo Liu1,2, Kaifeng Yin5,6, Jing Lan1,2,7.
Abstract
BACKGROUND: Fine osseointegration is the basis of long-term survival of implant. In our previous study, we observed a strong correlation between hyperlipidemia and compromised osseointegration. MicroRNA-29a-3p (miR-29a-3p) has been discovered to participate in bone marrow mesenchymal stem cells (BMSCs) differentiation. However, the role and the underlying mechanisms of hyperlipidemia and miR-29a-3p in osseointegration still remain obscure.Entities:
Keywords: Dvl2; Fzd4; Hyperlipidemia; Osseointegration; miR-29a-3p
Year: 2018 PMID: 30386554 PMCID: PMC6203977 DOI: 10.1186/s13578-018-0254-y
Source DB: PubMed Journal: Cell Biosci ISSN: 2045-3701 Impact factor: 7.133
Primers used for qRT-PCR
| Gene | Forward primer sequence (5′–3′) | Reverse primer sequence (5′–3′) |
|---|---|---|
| ALP | TGAGCGACACGGACAAGAAG | GCCTGGTAGTTGTTGTGAGCAT |
| Runx2 | CACAAGTGCGGTGCAAACTT | AATGACTCGGTTGGTCTCGG |
| Dvl2 | TCCACCATTACCCCCTTTGC | GCCATGCTCACTGCTGTCT |
| Fzd4 | GGAAGGACCAGGTGACGAAG | GGAATATGATGGGGCGCTCA |
| GAPDH | TGATGGGTGTGAACCACGAG | CTGATGGGTGTGAACCACGAG |
| miR-29a-3p | UAACCGAUUUCAAAUGGUGCUA | |
Antibodies used for western blotting
| Name | Description | Manufacturer |
|---|---|---|
| Anti-ALP | Rabbit monoclonal, 140 kDa | CST (#3192) |
| Anti-Runx2 | Rabbit monoclonal, 170 kDa | CST (#3179) |
| Anti-Dvl2 | Mouse monoclonal, 65 kDa | Abcam (ab181770) |
| Anti-Fzd4 | Rabbit monoclonal, 70 kDa | CSB-PA706537 |
The serum TC, TG, HDL and LDL of two groups
| TC | TG | HDL | LDL | |
|---|---|---|---|---|
| Normal range | 1.64 ± 0.21 | 1.01 ± 0.46 | 0.91 ± 0.15 | 0.24 ± 0.05 |
| Control group | 1.45 ± 0.22 | 0.73 ± 0.12 | 1.10 ± 0.16 | 0.29 ± 0.66 |
| Experiment group | 3.45 ± 0.65* | 1.74 ± 0.68* | 1.07 ± 0.22* | 0.65 ± 0.12* |
Values are mean ± SD in mmol/l, *P < 0.05 was considered statistically significant
Fig. 1MiR-29a-3p expression was deregulated in hyperlipidemia rats along with impaired osseointegration. a HE stained hard tissue slices were used to assess the osseointegration of implant periphery bone both of normal and HF groups. b qRT-PCR analysis was used to determine the relative expression levels of miR-29a-3p, ALP mRNA and Runx2 mRNA in peri-implant bone tissues of HF group and normal group. Results were represented as mean ± SD. *P < 0.05
Fig. 2MiR-29a-3p overexpression facilitated osseointegration and miR-29a-3p inhibition suppresses osseointegration in vivo. Hard tissue slices of implant periphery miR-29a-3p overexpressed bone and overexpression-nc bone (a) and miR-29a-3p inhibited bone and inhibitor-nc bone (b). Relative expression levels of miR-29a-3p, ALP mRNA and Runx2 mRNA in miR-29a-3p-enhancer, miR-29a-3p-inhibitor or enhancer/inhibitor-nc bone tissues (c). Results are represented as mean ± SD. *P < 0.05, **P < 0.01
Fig. 3MiR-29a-3p expression was decreased in experiment group correlated with compromised osteogenic differentiation. a FACS was performed to identify BMSCs and assess the purity of BMSCs. Immunofluorescence was carried out to show the cytoskeletal structures and the introcellular location of ALP proteins (b), and Runx2 proteins (c). d ALP staining and ALP activity assays were applied to detect osteogenic differentiation. e ARS staining was used to determine the mineralization of osteoblasts, mn: mineralized nodule. f Oil red O staining was conducted to analyze the adipogenesis of osteoblasts, drop: lipid drop. g Relative expression levels of miR-29a-3p, ALP mRNA and Runx2 mRNA in control and experiment groups. h Western blotting was used to detect ALP and Runx2 proteins in control and experiment groups. Results are represented as mean ± SD of three independent experiments. *P < 0.05
Fig. 4Overexpressed miR-29a-3p forced osteogenic differentiation and miR-29a-3p inhibitor reduced differentiation in vitro. BMSCs were transfected with miR-29a-3p enhancer, enhancer-nc, miR-29a-3p inhibitor, or inhibitor-nc, followed by the measurement of osteogenic differentiation by ALP staining (a), miR-29a-3p, ALP mRNA and Runx2 mRNA (b), and ALP and Runx2 proteins (c). Results are represented as mean ± SD. *P < 0.05
Fig. 5miR-29a-3p directly suppressed Dvl2 and Fzd4 expression by binding to their 3′-UTR. a mRNA levels of Dvl2 and Fzd4 in peri-implant bone tissue in hyperlipidemia and normal rat models. The mRNA levels of Dvl2 and Fzd4 (b) and protein levels of Dvl2 and Fzd4 (c) in BMSCs transfected with miR-29a-3p enhancer, enhancer-nc, miR-29a-3p inhibitor, or inhibitor-nc. d Luciferase reporters assay was performed in 293T cells after transfected with miR-29a-3p-WT enhancer reporter, miR29a-3p-MUT enhancer reporter or miR-WT/MUT NC. Results are represented as mean ± SD. *P < 0.05